Genprex, Inc.

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

GNPX$2.06-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	Year Ended
	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$7,830,855	$1,601,660
Prepaid expenses and other	525,928	475,807
Total current assets	8,356,783	2,077,467
Property and equipment, net	—	—
Research and development supplies	1,802,228	2,046,858
Total non-current assets	1,802,228	2,046,858
Total assets	$10,159,011	$4,124,325
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$743,070	$1,074,295
Other current liabilities	1,431,565	1,429,875
Total current liabilities	2,174,635	2,504,170
Non-current liabilities:
Derivative liabilities	22,500	—
Total liabilities	2,197,135	2,504,170
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—
Common stock $0.001 par value: 200,000,000 shares authorized; 3,291,488 and 217,234 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	3,291	217
Additional paid-in capital	178,986,981	156,419,381
Accumulated deficit	(171,028,396)	(154,799,443)
Total stockholders' equity	7,961,876	1,620,155
Total liabilities and stockholders' equity	$10,159,011	$4,124,325

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.